Prominent investor Ashish Kacholia has taken an equity position in TechInvention Lifecare Limited, a Mumbai-based biotechnology firm that develops vaccines for infectious diseases. The company confirmed the investment in a statement issued this week.
Funding to support a new vaccine manufacturing hub
According to TechInvention, the funds will help accelerate the construction of a new vaccine manufacturing facility in Navi Mumbai. The plant is designed to support the large-scale production of several vaccine candidates currently in its pipeline. These candidates use a range of technologies, including recombinant subunit, conjugate, VLP, adenoviral vector and mRNA platforms, reflecting the company’s effort to broaden its scientific base.
Kacholia said the investment aligns with his interest in supporting companies working on medical products with a broad public impact. In a brief comment, he said he looked forward to seeing the company’s vaccines reach people in India and abroad.
TechInvention’s founder and chief executive, Syed S. Ahmed, said the financial backing strengthens the company’s ongoing work on what it calls the Global Collaborative Centre for Medical Counter Measures, the internal name for its manufacturing expansion. He added that the investment signals confidence in India’s potential to supply accessible vaccines to low- and middle-income countries.
Company growth
Since it launched in 2016, TechInvention says it has posted a 65 percent compound annual growth rate. The company has appeared in Forbes India’s list of firms with global potential, received a biopharma industry award, and earned a low-risk credit rating from Dun & Bradstreet. These milestones, the company noted, reflect steady momentum as it moves to scale its operations.
TechInvention described Kacholia’s involvement as a turning point in its transition from an R&D-driven organization to one preparing for commercial production. The company said the investment supports its push to expand vaccine access and strengthen global preparedness for future health threats.
